Article

Using registry data to estimate the effects of long-term treatment use in cystic fibrosis

2019-01-01

Abstract excerpt

Cystic fibrosis (CF) is a disease affecting over 10,000 people in the UK. It has no cure, but there are many treatments to help improve health. Randomised controlled trials are the gold standard for establishing treatment efficacy, but most trials for CF treatments have no more than one year of follow-up. In practice treatments are commonly used for many years, and it is therefore important to evaluate their long-...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 057a9498-d1f6-5abe-97e3-3cb1e2c6b332
DOI: 10.17037/pubs.04652092

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Using registry data to estimate the effects of long-term treatment use in cystic fibrosisDOI 10.17037/pubs.04652092Read

Real-world impact of Elexacaftor-Tezacaftor-Ivacaftor treatment in young people with Cystic Fibrosis: A longitudinal studySemantic proximity Read

Treatment patterns in people with cystic fibrosis: have they changed since the introduction of ivacaftor?Semantic proximity Read

Using Negative Control Outcomes and Difference-in-Differences Analysis to Estimate Treatment Effects in an Entirely Treated Cohort: The Effect of Ivacaftor in Cystic Fibrosis.Semantic proximity Read

Tezacaftor-ivacaftor use in routine care of adults with cystic fibrosis: a medicine use evaluation.Semantic proximity Read

Projecting the impact of triple CFTR modulator therapy on intravenous antibiotic requirements in cystic fibrosis using patient registry data combined with treatment effects from randomised trials.Semantic proximity Read

Calibration and validation of modeled 5-year survival predictions among people with cystic fibrosis treated with the cystic fibrosis transmembrane conductance regulator modulator ivacaftor using United States registry data.Semantic proximity Read

Rate of Uptake of Ivacaftor Use after U.S. Food and Drug Administration Approval among Patients Enrolled in the U.S. Cystic Fibrosis Foundation Patient Registry.Semantic proximity Read

Patient perspectives following initiation of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis and advanced lung disease.Semantic proximity Read

Factors associated with prescription of elexacaftor/tezacaftor/ivacaftor among people with cystic fibrosis aged 12 years or older with at least one F508del allele.Semantic proximity Read

Pregnancy and perinatal outcomes for women with Cystic Fibrosis: a UK population-based cross-sectional study, 2003-2017Semantic proximity Read

Ivacaftor for cystic fibrosis: An evaluation of real world utilisation and expenditure in the Irish Healthcare Setting.Semantic proximity Read

Decreases in Rhinology Care Utilization by People with Cystic Fibrosis on Highly Effective Modulator Therapy.Semantic proximity Read